Hyperlipidemia - PACE-CME

Episodes 17-26 of 26

MinuteCE®
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
1.00 credit 3 episodes
- Erik Stroes
- P. Gabriel Steg, MD
- Pam R. Taub, MD, FACC, FASPC
1.00 credit 3 episodes
MinuteCE®
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
1.00 credit 4 episodes
- Kausik Ray, MBChB, MD, MPhil
- Lale Tokgözoğlu, MD
- Prof. dr. Fabrice Martens
- Erin Michos
1.00 credit 4 episodes
Oral cholesterol-lowering therapies: The basis of prevention
Oral cholesterol-lowering therapies: The basis of prevention
MinuteCE®
Oral cholesterol-lowering therapies: The basis of prevention
1.00 program credit
- Lale Tokgözoğlu, MD
1.00 program credit
PCSK9i: Benefits across the spectrum of cardiovascular disease
PCSK9i: Benefits across the spectrum of cardiovascular disease
MinuteCE®
PCSK9i: Benefits across the spectrum of cardiovascular disease
1.00 program credit
- Prof. dr. Fabrice Martens
1.00 program credit
The evolving need and challenges to reach LDL-c targets in high-risk patients
The evolving need and challenges to reach LDL-c targets in high-risk patients
MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program credit
- Kausik Ray, MBChB, MD, MPhil
1.00 program credit
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program credit
- Erin Michos
1.00 program credit
Unmet needs in lowering LDL-c
Unmet needs in lowering LDL-c
MinuteCE®
Unmet needs in lowering LDL-c
1.00 program credit
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
1.00 program credit
New insights on CETP inhibition from genetic research and clinical trials
New insights on CETP inhibition from genetic research and clinical trials
MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program credit
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
1.00 program credit
MinuteCE®
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
1.00 credit 3 episodes
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Roxana Mehran, MD
1.00 credit 3 episodes
Exploring the role of a novel CETP inhibitor in lipid management
Exploring the role of a novel CETP inhibitor in lipid management
MinuteCE®
Exploring the role of a novel CETP inhibitor in lipid management
1.00 program credit
- Roxana Mehran, MD
1.00 program credit

Previous
1
2
Next

2/2